SCOLR Pharma Inc.
19204 Northcreek Parkway
Suite 100
Bothell,
WA 98011
United States - Map
Phone: 425-368-1050
Fax: 425-368-1051
Web Site: http://www.scolr.com
| SCOLR Pharma, Inc., a pharmaceutical company, develops and formulates prescription, over-the-counter, and nutritional products. The company uses its controlled delivery technology platform and develops water soluble and insoluble drugs, as well as high and low dose drugs; analgesic, cardiovascular, diabetes, anti-nausea, and pulmonary products; and dietary supplement products, including combinations of glucosamine and chondroitin, calcium, and other dietary products. Its products include Ibuprofen, an analgesic used for the treatment of pain, fever, and inflammation; Pseudoephedrine, a decongestant that is used to relieve sinus pressure related to allergies and common cold; Raloxifene, an ingredient in Evista, which is used to prevent and treat osteoporosis; Ondansetron, a drug in Zofran that is used for anti-nausea and vomiting associated with chemotherapy and radiation treatments for cancer; Rivastigmine, an ingredient in Exelon used for the management of Alzheimers disease; and Risperidone, an ingredient in Risperdal that is used for the management of schizophrenia and bipolar mania. The company has a strategic alliance with Perrigo Company for the manufacture, marketing, distribution, and sale of certain dietary supplements in the United States; research collaboration with BioCryst Pharmaceuticals to develop an oral formulation of peramivir, an antiviral compound for the treatment of seasonal and life threatening influenza; and a collaboration and license agreement with Dr. Reddy's Laboratories to pursue the development and commercialization of an oral prescription drug product. The company was formerly known as SCOLR, Inc. and changed its name to SCOLR Pharma, Inc. in July 2004. SCOLR Pharma, Inc. was founded in 1983 and is headquartered in Bothell, Washington. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Stephen J. Turner , 38
Chief Exec. Officer and Pres |
$
252.00K |
$
0 | Mr. Richard M. Levy , 51
Chief Financial Officer, Principal Accounting Officer and VP of Fin. |
$
226.00K |
$
0 | Mr. Alan M. Mitchel , 52
Chief Legal Officer and Sr. VP of Bus. & Legal Affairs |
$
295.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.01% Nasdaq 
1.13%
Profile
